logo
Plus   Neg
Share
Email

Eli Lilly, Incyte Report Positive Results For Baricitinib In Alopecia Areata Treatment- Quick Facts

Eli Lilly and Company (LLY) and Incyte (INCY) announced positive topline results from the late-stage study of baricitinib for the treatment of adults with severe alopecia areata (AA), an autoimmune disease that causes patchy hair loss on the scalp, face and sometimes on other areas of the body that can progress.

The phase III study of once-daily baricitinib 2-mg and 4-mg, dubbed BRAVE-AA2, met the primary efficacy endpoint at Week 36, showing a statistically significant improvement in scalp hair regrowth compared to those randomized to placebo, the companies said.

Data from an additional Phase III study of baricitinib in AA is expected in the first half of this year.

Baricitinib is approved and commercially available as Olumiant in the U.S. and more than 70 countries as a treatment for adults with moderate to severe active rheumatoid arthritis. In the European Union and Japan this is meant to treat adult patients with moderate to severe atopic dermatitis who are candidates for systemic therapy.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
ViacomCBS Inc. announced plans to combine CBS News and the CBS Television Stations. The journalistic and business operations of both will be combined into one divisional and leadership structure. Neeraj Khemlani and Wendy McMahon were appointed as presidents and co-heads of the newly formed division, effective early next month. Retail major Target Corp. is recalling about 44,350 units of Cat & Jack Baby Heart Ears Rompers, citing choking risks to children, the U.S. Consumer Product Safety Commission said in a statement. The recall involves rompers sold in various sizes from newborn to 24 months. The rompers were manufactured in Vietnam, and sold at Target stores across the United States and online. Alcoa Corp. (AA), the largest producer of aluminum in the US, Thursday reported a first-quarter profit that more than doubled from a year ago, driven by increased shipments and prices. Both adjusted earnings and revenues for the quarter trumped Wall Street analysts' estimates. Pittsburgh-based Alcoa...
Follow RTT